An interventional study of Irreversible electroporation in Cholangiocarcinoma and Interventional Imaging, sponsored by Poitiers University Hospital. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-13.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment
The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.
930 studies on the registry are indexed under Cholangiocarcinoma; 292 are open to participants now.
Browse Cholangiocarcinoma studies →Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Electrodes
Procedure: Irreversible electroporation
Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
The success rate of the technique, being the realisation of the irreversible electroporation.
The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%
Time frame: At Day 0
No study locations are listed for this record.
Ran from May 2021 to primary completion in Jun 2022, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →